A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension
Trial details
- Registry ID
- NCT06785454
- Phase
- Phase 2
The PDUFA goal date for Lorundrostat in hypertension in combination with other antihypertensive drugs is 22 Dec 2026, as disclosed by Mineralys Therapeutics Inc. (MLYS).
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and HypertensionNCT06785454 | MLYS | Phase 2 | Completed | 2025-12-17Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-12-22Day | LorundrostatMineralys Therapeutics Inc. · MLYS | Company-disclosed PDUFA goal dateAnnounced review target | hypertension in combination with other antihypertensive drugs | Open original sourceRead source excerptWe submitted our NDA to the FDA in December 2025 for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs. The FDA accepted the NDA submission and provided us with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026 for lorundrostat. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2026-12-22Day | LorundrostatMineralys Therapeutics Inc. · MLYS | Company-disclosed PDUFA goal dateAnnounced review target | treatment of hypertension in combination with other antihypertensive drugs | Open original sourceRead source excerptThe U.S. Food and Drug Administration (FDA) continues its review of the NDA for lorundrostat for the treatment of hypertension in combination with other antihypertensive drugs, with a Prescription Drug User Fee Act (PDUFA) target date of December 22, 2026. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |